Japan becomes first country to approve Roche’s alectinib for people with a specific form of advanced lung cancer
4 July 2014 | By Roche
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib...
List view / Grid view
News
Marketing and manufacturing approval in Japan received for CANAGLU® tablets 100mg
4 July 2014 | By Daiichi Sankyo
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, CANAGLU® tablets 100mg (generic name: canagliflozin hydrate, hereafter, CANAGLU®) in Japan, for the treatment of patients with type 2 diabetes mellitus...
Teva receives CHMP positive opinion for Seasonique® extended-regimen contraceptive for marketing authorization in several European countries
4 July 2014 | By Teva
An extended regimen oral contraceptive that provides quarterly menses – a new concept for women in Europe...
Prime Minister warns of global threat of antibiotic resistance
3 July 2014 | By Department of Health
The Prime Minister David Cameron called for global action to tackle the growing threat of resistance to antibiotics...
Ebola cases in West Africa continue to rise
3 July 2014 | By Public Health England
PHE and other stakeholders providing technical support to the affected countries...
Mass spectrometry-based metabolics – an exclusive online-only article from Tun-Li Shen at Brown University
3 July 2014 | By Tun-Li Shen, Brown University
Tun-Li Shen provides a brief overview of the gas chromatography mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS) instrumentation platforms used in untargeted metabolomics studies...
GSK statement on UK Government-initiated review of antibiotic resistance
3 July 2014 | By GlaxoSmithKline
“We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance..."
Midatech appoints Nick Robbins-Cherry as Finance Director
2 July 2014 | By Midatech
Midatech Ltd. is pleased to announce that Nick Robbins-Cherry has been appointed as Finance Director, further strengthening the Company’s senior management team...
Pfizer Inc. receives kosher certification for Elelyso™ (taliglucerase alfa) for injection, for the treatment of Type 1 Gaucher disease
2 July 2014 | By Pfizer
Pfizer Inc. announced that the Orthodox Union has granted kosher certification to ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease...
Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat® fixed-dose combination in COPD
2 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft Mist™ Inhaler...
Roche announces definitive agreement to acquire Seragon Pharmaceuticals
2 July 2014 | By Roche
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer...
Actavis plc appoints new members and announces changes to Board of Directors following close of Forest Laboratories, Inc. acquisition
2 July 2014 | By Actavis
Actavis plc announced the appointment of three new members to the Company's Board of Directors, including Actavis' newly appointed CEO and President, Brenton L. Saunders...
12th Takamine Memorial Daiichi Sankyo Prize winner announced
2 July 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that its affiliated foundation, the Daiichi Sankyo Foundation of Life Science has awarded its 12th Takamine Memorial Daiichi Sankyo Prize...
Torch V10.3 delivers intuitive visualization and analysis tools for multiple parameter optimization
1 July 2014 | By kdm communications
Cresset, innovative provider of computational chemistry software and services, announces the release of Torch V10.3...
GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma
1 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the submission of a supplemental New Drug Application to the US Food and Drug Administration for a fixed dose combination of the inhaled corticosteroid, fluticasone furoate and the long-acting beta2 agonist, vilanterol...
